episode 945: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Research assistant position with Amy Rosenfeld (pdf)
- Support MicrobeTV with a Spike t-shirt at Vaccinated.US
- A healthcare-associated infection with monkeypox virus (OFID)
- Air and surface sampling for monkeypox virus (The Lancet)
- Misrepresentation & nonadherence in COVID-19 public health measures (JAMA)
- Tolerability and immunogenicity of a COVID-19 vaccine (The Lancet)
- PAXLOVID patient eligibility screening checklist (FDA)
- Evaluation of symptomatic disease rebound following PAXLOVID (CID)
- Outpatient treatment with Remdesivir in patients at high risk (OFID)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Molnupiravir as early treatment for adults with COVID-19 (SSRN)
- Outcomes among confirmed cases and matched comparison group in long-COVID (Nature)
- Dr. Griffin’s treatment guide (pdf)
- Contribute to Floating Doctors fundraiser at PWB
- Letters read on TWiV 945
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv